University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 1 of 16
Breakthrough - T1DM and Chronic Kidney Disease
NCT07592000
Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
NCT07354100
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
NCT07603856
Implementation of Tobacco Cessation Programming at Community Behavioral Health Sites
NCT06837220
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
NCT07405424
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
NCT06824818
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
NCT06446661
Geriatric Assessment and Technology Evaluation in Prostate Cancer
NCT06215508
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
NCT07294677
Total Intravenous Anesthesia vs Spinal Anesthesia in Patients Undergoing Unilateral Primary Total Knee Arthroplasty
NCT07672301
Achieving Routine Intervention and Screening for Emotional Health
NCT06887049
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
NCT07290621
Effect of Early Parent Education on Children's Sleep
NCT07515534
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
NCT07126509
Prospective Assessments Following Immediate Lymphatic Reconstruction
NCT07227467
SGLT2i in Kidney Stones
NCT07055282
PSMA PET for Surveillance After Focal Therapy
NCT07115914
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
NCT06693310
Type 1 Diabetes and Obstructive Sleep Apnea
NCT06915831
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT07065630
Oxalate and Citrate in Humans - Response to Citrate
NCT06944223
Investigating Periprosthetic Fracture Cultures in Arthroplasty
NCT06952738
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
NCT06912087
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
NCT04107077
Hypofractionation (Radiation) Trial for Multiple Myeloma
NCT06270888
Investigating Patient Satisfaction With Smart Knee Implants
NCT06968143
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
NCT06871111
Auricular Acupressure in Prehabilitation
NCT06516198
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
NCT06669572
FITting Non-invasive Tests in Lynch Syndrome Surveillance
NCT06898996
Tibial IMN Vs. Tibial Micromotion IMN
NCT06976801
Drug Effects on Mood and Behavior - Expectancy
NCT07061886
Mood Effects of Serotonin Agonists: Depression
NCT07017478
A Bionic Breast Project Using Neuroprosthesis to Reduce Chronic Pain After Mastectomy
NCT06382272
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NCT06785324
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
NCT05790213
Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
NCT06859164
Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults
NCT06395415
New Strategies to Enhance Smoking Cessation
NCT06751927
Work2Prevent Plus: Structural Intervention to Promote HIV Care in Black Sexual Minority Men
NCT06894199
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
NCT06499857
Does Ethyl Chloride Spray Work?
NCT06651788
Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain
NCT06635889
Recovery Legal Care Clinical Trial
NCT06618794
Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk
NCT06965686
Piloting a Culturally Adapted Suicide Prevention for Black Students in Chicago
NCT07125144
Dysbiosis & Long COVID
NCT06825819
AYA OMGYES Sexual Health Study
NCT06868121
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT05726292
Oxytocin Pharmacokinetics and Pharmacodynamics
NCT05488457
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Chicago pipeline card: 796 registered trials from official public datasets.Report a data error.